Marquette Asset Management »

Adaptimmune Therapeutics shares owned by Marquette Asset Management

Quarter-by-quarter ownership of Adaptimmune Therapeutics (ADAP) shares owned by Marquette Asset Management from 13F filings

Historical chart of Marquette Asset Management investment in Adaptimmune Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Adaptimmune Therapeutics held by Marquette Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adaptimmune Therapeutics by Marquette Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $78k 99k 0.79
2023-09-30 $78k 99k 0.78

More positions owned by Marquette Asset Management

Schwab Strategic Tr Us Lcap Gr Etf (SCHG)
Dimensional Etf Trust Intl Core Eqt Mk (DFAI)
Schwab Strategic Tr Us Dividend Eq (SCHD)
American Centy Etf Tr Us Sml Cp Valu (AVUV)
Ishares Tr Rus 1000 Grw Etf (IWF)
Ishares Tr Core Us Aggbd Et (AGG)
Victory Portfolios Ii Short Trm Bd Etf (USTB)
Vanguard Index Fds Mid Cap Etf (VO)
Spdr Ser Tr S&p Kensho New (KOMP)
Invesco Exchange Traded Fd T S&p500 Pur Gwt (RPG)
Dimensional Etf Trust Emerging Mkts Va (DFEV)
Dimensional Etf Trust Emgr Cre Eqt Mng (DFAE)
American Centy Etf Tr Intl Smcp Vlu (AVDV)
Ishares Tr Rus 1000 Val Etf (IWD)
First Tr Dow Jones Select Mi Com Shs Annual (FDM)

View all positions for Marquette Asset Management

Top funds holding Adaptimmune Therapeutics

NEA Management Company
Baillie Gifford & Co
Long Focus Capital Management
Baker Bros. Advisors
Partner Fund Management
Bank of America Corporation
Tang Capital Management
Citadel Advisors
Syncona Portfolio
Jpmorgan Chase & Co
Redmile Group
GSA Capital Partners
Acuitas Investments
Millennium Management
DAFNA Capital Management

View all funds holding Adaptimmune Therapeutics